vTv Therapeutics (VTVT) vs. Its Rivals Critical Analysis

vTv Therapeutics (NASDAQ:VTVT) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare vTv Therapeutics to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, profitability, earnings, dividends and valuation.

Risk and Volatility

vTv Therapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, vTv Therapeutics’ peers have a beta of -3.79, meaning that their average share price is 479% less volatile than the S&P 500.

Valuation and Earnings

This table compares vTv Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
vTv Therapeutics	$1.02 million	-$26.97 million	-22.22
vTv Therapeutics Competitors	$3.53 billion	$3.15 billion	547.98

vTv Therapeutics’ peers have higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and target prices for vTv Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1	1	6	1	2.78
vTv Therapeutics Competitors	7768	13854	25724	1032	2.41

vTv Therapeutics presently has a consensus target price of $55.83, indicating a potential upside of 137.08%. As a group, “Pharmaceuticals” companies have a potential upside of 26.48%. Given vTv Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe vTv Therapeutics is more favorable than its peers.

Profitability

This table compares vTv Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
vTv Therapeutics Competitors	-2,372.59%	-220.83%	-15.99%

Summary

vTv Therapeutics beats its peers on 8 of the 13 factors compared.

About vTv Therapeutics

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.